title: Surgical treatment of trigeminal neuralgia.
abstract: Patients with medically intractable trigeminal neuralgia characterized by paroxysmal, triggered, trigeminally distributed pain are excellent candidates for neurosurgical intervention, which can not only relieve the pain of trigeminal neuralgia, but also eliminate the unpleasant side effects of medicines used to treat it. The two major neurosurgical choices are percutaneous denervation and microvascular decompression (MVD). Percutaneous denervation is done best when the surgeon has available radiofrequency and glycerol and uses one, the other, or both depending on technical circumstances that pertain to each patient. The percutaneous denervation is less likely than MVD to cause death, stroke, facial weakness, or hearing loss, but more likely to be associated with recurrence or dysesthesias. Patients with multiple sclerosis, medical illness, or who are elderly are much better candidates for percutaneous denervation. For any patient, a number of other factors also must be considered before deciding on a particular procedure. These include response to previous interventions, ability to tolerate carbamazepine, risk tolerance for various complications, preference regarding duration of hospital stay and postoperative recovery, presence of pain outside the trigeminal distribution, and findings on a high resolution magnetic resonance imaging (MRI) scan.
authors.forename: R
authors.initials: R
authors.lastname: Brisman
mesh_terms: D003131:Combined Modality Therapy; D019299:Decompression, Surgical; D003714:Denervation; D004564:Electrocoagulation; D005990:Glycerol / Q000627:therapeutic use; D006801:Humans; D010525:Peripheral Nerves / Q000601:surgery; D014277:Trigeminal Neuralgia / Q000188:drug therapy / Q000601:surgery*; D014656:Vascular Surgical Procedures
chemical_list: D005990:Glycerol